Enteroviruses

  • Joseph L. Melnick
Chapter
Part of the Infectious Agents and Pathogenesis book series (IAPA)

Abstract

The polioviruses are the only enteroviruses for which there is sufficient information to devote a chapter to their neurotropism and prevention by immunologic methods. They are thus the main feature of this chapter. However, it is important to bear in mind that other enteroviruses may also invade the central nervous system (CNS). Especially prominent in this regard are coxsackie B viruses and enterovirus type 71, but other nonpolio enteroviruses also have been associated with CNS disease.

Keywords

Central Nervous System Disease Aseptic Meningitis Oral Poliovirus Vaccine Enterovirus Infection Poliovirus Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paul, J. R., 1971, A History of Poliomyelitis, Yale University Press, New Haven.Google Scholar
  2. 2.
    Melnick, J. L., 1983, Portraits of viruses: The picornaviruses, Intervirology 20: 61–100.PubMedCrossRefGoogle Scholar
  3. 3.
    Melnick, J. L., 1990, Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, in: Virology, 2nd ed. ( B. N. Fields, D. M. Knipe, R. M. Chanock, M. Hirsch, J. L. Melnick, T. Monath, and B. Roizman, eds.), Raven Press, New York, pp. 549–605.Google Scholar
  4. 4.
    Mirkovic, R. R., Kono, R., Yin-Murphy, M., Sohier, R., Schmidt, N. J., and Melnick, J. L., 1973, Enterovirus type 70: The etiologic agent of pandemic acute haemorrhagic conjunctivitis, Bull. WHO 49: 341–346.PubMedGoogle Scholar
  5. 5.
    Nomoto, A., and Wimmer, E., 1987, Genetic studies of the antigenicity and the attenuation phenotype of poliovirus, in: Molecular Basis of Virus Disease, Symposium 40, Soc. Gen. Microbiol. ( W. D. Russell and J. W. Almond, eds.), Cambridge University Press, Cambridge, pp. 107–134.Google Scholar
  6. 6.
    Hogle, J. M., Chow, M., and Filman, D. J., 1985, Three-dimensional structure of poliovirus at 2.9 A resolution, Science 229: 1358–1365.PubMedCrossRefGoogle Scholar
  7. 7.
    Burke, K. L., Dunn, G., Ferguson, M., Minor, P. D., and Almond, J. W, 1988, Antigen chimaeras of poliovirus as potential new vaccines, Nature 332: 81–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Murray, M. G., Kuhn, R. J., Arita, M., Kawamura, N., Nomoto, A., and Wimmer, E., 1988, Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro that elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys, Proc. Natl. Acad. Sci. U.S.A. 85: 3203–3207.PubMedCrossRefGoogle Scholar
  9. 9.
    Sabin, A. B., Krumbeigel, E. R., and Wigand, R., 1958, ECHO type 9 virus disease: Virologically controlled clinical and epidemiologic observations during 1957 epidemic in Milwaukee with notes on concurrent similar diseases associated with Coxsackie and other ECHO viruses, Am. J. Dis. Child. 96: 197–219.Google Scholar
  10. 10.
    Hall, C. E., Cooney, M. K., and Fox, J. P., 1970, The Seattle Virus Watch Program. I. Infection and illness experience of Virus Watch families during a community-wide epidemic of echovirus type 30 aseptic meningitis, Am. J. Publ. Health 60: 1456–1465.CrossRefGoogle Scholar
  11. 11.
    Grist, N. R., Bell, E. J., and Assaad, F., 1978, Enteroviruses in human disease, Prog. Med. Virol. 24: 114–157.PubMedGoogle Scholar
  12. 12.
    World Health Organization, 1987–1989, Poliomyelitis in 1985; Poliomyelitis in 1986, 1987, and 1988, Weekly Epidemiol. Rec. 62:273–280; 64: 273–279.Google Scholar
  13. 13.
    WHO EPI Global Advisory Group, 1985, Summary of conclusions and recommendations, Weekly Epidemiol. Rec. 60: 13–16.Google Scholar
  14. 14.
    LaForce, E. M., Lichnevski, M. S., Keja, J., and Henderson, R. H., 1980, Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries, Bull. WHO 58: 609–620.PubMedGoogle Scholar
  15. 15.
    Foster, S. O., Kesseng-Maben, G., N jie, H., and Coffi, E., 1984, Control of poliomyelitis in Africa, Rev. Infect. Dis. 6: S433 — S437.PubMedCrossRefGoogle Scholar
  16. 16.
    Grist, N. R., and Bell, E. J., 1984, Paralytic poliomyelitis and nonpolio enteroviruses: Studies in Scotland, Rev. Infect. Dis. 6: S385 — S386.PubMedCrossRefGoogle Scholar
  17. 17.
    Melnick, J. L., 1984, Enterovirus type 71 infections: A varied clinical pattern sometimes mimicking paralytic poliomyelitis, Rev. Infect. Dis. 6: S387 — S390.PubMedCrossRefGoogle Scholar
  18. 18.
    Voroshilova, M. K., and Chumakov, M. P., 1959, Poliomyelitis-like properties of AB-IVCoxsackie A7 group of viruses, Prog. Med. Virol. 2: 106–170.Google Scholar
  19. 19.
    Kono, R., Miyamura, K., Tajiri, E., Shiga, S., Sasagawa, A., Irani, P. E, Katrak, S. M., and Wadia, N. H., 1974, Neurologic complications associated with acute hemorrhagic conjunctivitis virus infection and its serological confirmation, J. Infect. Dis. 129: 590–593.PubMedCrossRefGoogle Scholar
  20. 20.
    Sells, C. J., Carpenter, R. L., and Ray, C. G., 1975, Sequelae of central-nervous-system enterovirus infections, N. Engl. J. Med. 293: 1–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Melnick, J. L., Proctor, R. O., Ocampo, A. R., Diwan, A. R., and Ben-Porath, E., 1966, Free and bound virus in serum after administration of oral poliovirus vaccine, Am. J Epidemiol. 84: 329–342.PubMedGoogle Scholar
  22. 22.
    Paul, J. R., Riordan, J. T., and Melnick, J. L., 1951, Antibodies to three different antigenic types of poliomyelitis virus in sera from North Alaskan Eskimos, Am. J. Hyg. 54: 275–285.PubMedGoogle Scholar
  23. 23.
    Melnick, J. L., Clark, N. A., and Kraft, L. M., 1950, Immunological reactions of the Coxsackie viruses. III. Cross-protection tests in infant mice born of vaccinated mothers. Transfer of immunity through the milk, J. Exp. Med. 92: 499–505.PubMedCrossRefGoogle Scholar
  24. 24.
    Ogra, P. L., Fishaut, M., and Gallagher, M. R., 1980, Viral vaccination via the mucosal routes, Rev. Infect. Dis. 2: 352–369.PubMedCrossRefGoogle Scholar
  25. 25.
    van Wezel, A. L., van Steenis, G., Hannick, C. A., and Cohen, H., 1978, New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines, in: Developments in Biological Standardization, Vol. 41, Vaccinations in the Developing Countries, ( R. H. Regamey, ed.) S. Karger, Basel, pp. 159–168.Google Scholar
  26. 26.
    Zhaori, G., Sun, M., and Ogra, P. L., 1988, Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines, J. Infect. Dis. 158: 160–165.PubMedCrossRefGoogle Scholar
  27. 27.
    Yousef, G. E., Bell, E. J., Mann, G. E, Murugesan, V., Smith, D. G., McCartney, R. A., and Mowbray, J. E, 1988, Chronic enterovirus infection in patients with postviral fatigue syndrome, Lancet 1 :146–150.Google Scholar
  28. 28.
    Wilfert, C. M., Buckley, R. H., Mohanakumar, T., Griffith, J. E, Katz, S. L., Whisnant, J. K., Eggleston, P. A., Moore, M., Treadwell, E., Oxman, M. N., and Rosen, E. S., 1977, Persistent and fatal central-nervous-system echovirus infections in patients with agammaglobulinemia, N. Engl. J. Med. 296: 1485–1489.PubMedCrossRefGoogle Scholar
  29. 29.
    Ziegler, J. B., and Penny, R., 1975, Fatal echo 30 virus infection and amyloidosis in X-linked hypogammaglobulinemia, Clin. Immunol. Immunopathol. 3: 347–352.PubMedCrossRefGoogle Scholar
  30. 30.
    Hodes, D. S., and Espinoza, D. V., 1981, Temperature sensitivity of isolates of echovirus type 11 causing chronic meningoencephalitis in an agammaglobulinemic patient, J. Infect. Dis. 144: 377.Google Scholar
  31. 31.
    Melnick, J. L., 1988, Live attenuated poliovaccines, in: Vaccines ( S. A. Plotkin and E. A. Mortimer, Jr., eds.), W. B. Saunders, Philadelphia, pp. 115–157.Google Scholar
  32. 32.
    Salk, J., and Drucker, J., 1988, Noninfectious poliovirus vaccine, in: Vaccines ( S. A. Plotkin and E. A. Mortimer, Jr., eds.), W. B. Saunders, Philadelphia, pp. 158–181.Google Scholar
  33. 33.
    Robbins, E. C., 1988, Polio—historical, in: Vaccines ( S. A. Plotkin and E. A. Mortimer, Jr., eds.), W. B. Saunders, Philadelphia, pp. 98–114.Google Scholar
  34. 34.
    Schaap, G. J. P., Bijkerk, H., Coutinho, R. A., Kapsenberg, J. G., and van Wezel, A. L., 1984, The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic, Prog. Med. Virol. 29: 124–149.PubMedGoogle Scholar
  35. 35.
    Hovi, T., Huovilainen, A., Kuronen, T., Poyry, T., Salama, N., Cantell, K., Kinnunen, E., Lapinleimu, K., Roivainen, M., Stenvik, M., Silander, A., Thoden, C.J., Salminen, S., and Weckstrom, R, 1986, Outbreak of paralytic poliomyelitis in Finland: Widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population, Lancet 2: 1427–1435.CrossRefGoogle Scholar
  36. 36.
    Magrath, D. I., Evans, D. M. A., Ferguson, M., Schild, G. C., Minor, P. D., Horaud, E, Crainic, R., Stenvik, M., and Hovi, T., 1986, Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population, J. Gen. Virol. 76: 899–905.CrossRefGoogle Scholar
  37. 37.
    van Wezel, A. L., van Steenis, G., van der Marel, R, and Osterhaus, A. D. M. E., 1984, Inactivated poliovirus vaccine: Current production methods and new developments, Rev. Infect. Dis. 6: S335–S340.PubMedCrossRefGoogle Scholar
  38. 38.
    McBean, A. M., Thoms, M. L., Albrecht, P., Cuthie, J. C., Bernier, R., and the Field Staff and Coordinating Committee, 1988, Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines, Am. J. Epidemiol. 128: 615–628.Google Scholar
  39. 39.
    Stoeckel, R, Schlumberger M., Parent, G., Maire, B., van Wezel, A., van Steenis, G., Evans, A., and Salk, D., 1984, Use of killed poliovirus vaccine in a routine immunization program in West Africa, Rev. Infect. Dis. 6: S463–S466.PubMedCrossRefGoogle Scholar
  40. 40.
    Melnick, J. L., 1989, Poliomyelitis: A vanishing but not vanished disease, in: Current Topics in Medical Virology (Y. C. Chan, S. Doraisingham, and A. E. Ling, eds.), World Scientific, Singapore, pp. 226–253.Google Scholar
  41. 41.
    Cockburn, W. C., 1988, The work of the WHO Consultative Group on Poliomyelitis Vaccines, Bull. WHO 66: 143–154.PubMedGoogle Scholar
  42. 42.
    Nkowane, B. M., Wassilak, S. G. E, Orenstein, W. A., Bart, K. J., Schonberger, L. B., and Hinman, A. R., 1987, Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984, JA.M.A. 257: 1335–1340.Google Scholar
  43. 43.
    Lasch, E. E., Abed, Y., Abdulla, K., El Tibbi, A. G., Marcus, O., El Massri, M., Handscher, R., Gerichter, C. B., and Melnick, J. L., 1984, Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza, Rev. Inf. Dis. 6: S467–S470.CrossRefGoogle Scholar
  44. 45.
    Domok, I., Balayan, M. S., Fayinka, O. A., Skrtic, N., Soneji, A. D., and Harland, P. S. E. G., 1974, Factors affecting the efficacy of live poliovirus vaccines in warm climates, Bull. WHO 51: 333–347.PubMedGoogle Scholar
  45. 46.
    Robinson, D. A., 1982, Polio vaccination—a review of strategies, Trans. R. Soc. Trop. Med. Hyg. 76: 575–581.PubMedCrossRefGoogle Scholar
  46. 47.
    Sabin, A. B., 1985, Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world, J. Inf. Dis. 151: 420–436.CrossRefGoogle Scholar
  47. 48.
    Melnick, J. L., Ashkenazi, A., Midulla, V. C., Wallis, C., and Bernstein, A., 1963, Immunogenic potency of MgC12-stabilized oral poliovaccine, J.A.M.A. 185: 406–408.PubMedCrossRefGoogle Scholar
  48. 49.
    Peetermans, J., Colinet, G., and Stephenne, J., 1976, Activity of attenuated poliomyelitis and measles vaccines exposed at different temperatures, in: Proceedings of the Symposium on Stability and Effectiveness of Measles, Poliomyelitis and Pertussis Vaccines, Yugoslav Academy of Sciences and Arts, Zagreb, pp. 61–66.Google Scholar
  49. 50.
    Mirchamsy, H., Shafyi, A., Mahinpour, M., and Nazari, P., 1978, Stabilizing effect of magnesium chloride and sucrose on Sabin live polio vaccine, in: Developments in Biological Standardization, Vol. 41, Vaccinations in the Developing Countries ( R. H. Regamey, ed.) S. Karger, Basel, pp. 255–257.Google Scholar
  50. 51.
    Melnick, J. L., 1984, Recent developments in the worldwide control of poliomyelitis, in: Control of Virus Diseases ( E. Kurstak and E. G. Marusyk, eds.), Marcel Dekker, New York, pp. 3–31.Google Scholar
  51. 52.
    Lasch, E. E., Abed, Y., Marcus, O., Gerichter, C. B., and Melnick, J. L., 1986, Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country: five years after, in: Developments in Biological Standardization, Vol. 65, Use and Standardization of Combined Vaccines, S. Karger, Basel, pp. 137–143.Google Scholar
  52. 53.
    Nagington, J., Wreghitt, T. G., Gandy, G., Roberton, N. R. C., and Berry, P. J., 1978, Fatal echovirus 11 infections in outbreak in special-care baby unit, Lancet 2: 725.PubMedCrossRefGoogle Scholar
  53. 54.
    Modlin, J. E, 1986, Perinatal echovirus infection: Insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries, Rev. Infect. Dis. 8: 918–926.PubMedCrossRefGoogle Scholar
  54. 55.
    Nagington, J., Gandy, G., Walker, J., and Gray, J. J., 1978, Use of normal immunoglobulin in an echovirus outbreak in a special-care baby unit, Lancet 2: 443–446.Google Scholar
  55. 56.
    Patriarca, P. A., Onorato, I. M., Sklar, V. E. E, Schonberger, L. B., Kaminski, R. M., Hatch, M. H., Morens, D. M., and Forster, R. K., 1983, Acute hemorrhagic conjunctivitis. Investigation of a large-scale community outbreak in Dade County, Florida, J.A.M.A. 249: 1283–1289.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1992

Authors and Affiliations

  • Joseph L. Melnick
    • 1
  1. 1.Division of Molecular VirologyBaylor College of MedicineHoustonUSA

Personalised recommendations